What were the top developments in the pharma industry overall and the pharma manufacturing value chain in 2018? Takeda’s pending $62-billion acquisition of Shire, Cambrex’s $425-milllion acquisition of Halo Pharmaceuticals, a record-setting number of new drug approvals by the FDA, restructuring and pricing pressure in the US generics market, and setting up supply lines in a post-Brexit world are some the key developments. Read More
Pharma CEO Scorecard: The Movers and Shakers of 2018
by Patricia Van Arnum, DCAT Editorial Director
Refining business strategies to respond to changing market conditions is a constant in any industry, including the pharmaceutical industry. As the industry enters the final month of 2018, which pharmaceutical company CEOs have made the mark thus far in 2018 and should be on the industry’s radar for 2019? DCAT Value Chain Insights takes an inside look. Read More
Exclusively for DCAT member companies! Don't miss the results of our latest benchmarking study: Examining the Current and Future Alignment of the Pharma Customer–Supplier Relationship.
Patricia Van Arnum is Editorial Director at the Drug, Chemical & Associated Technologies Association (DCAT), where she is responsible for delivering informational services for DCAT members. She is editor of two weekly editorial newsletters, DCAT Value Chain Insights and Top Industry News. She also supports DCAT’s volunteer committees and task forces that develop educational programs and informational content for DCAT members. Read More
DCAT Value Chain Insights is produced and distributed by the Drug, Chemical and Associated Technologies Association.
